Invention Grant
- Patent Title: Methods of treating autoimmune disease or chronic inflammation with antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
-
Application No.: US16209627Application Date: 2018-12-04
-
Publication No.: US10906975B2Publication Date: 2021-02-02
- Inventor: Vibeke Westphal Stennicke , Christine Brender Read , Susanne Nedergaard Grell , Charlotte Wiberg , Rune Salbo , Anette Henriksen , Soeren Padkjaer
- Applicant: Novo Nordisk A/S
- Applicant Address: DK Bagsvaerd
- Assignee: Novo Nordisk A/S
- Current Assignee: Novo Nordisk A/S
- Current Assignee Address: DK Bagsvaerd
- Agency: Morgan, Lewis & Bockius LLP
- Priority: EP12155641 20120215,EP12158974 20120312,EP12176892 20120718
- Main IPC: A61K39/395
- IPC: A61K39/395 ; C07K16/00 ; C07K16/18 ; C07K16/28 ; A61K39/00
Abstract:
The invention relates to antibodies that are capable of specifically binding TREM-1 and preventing the activation of TREM-1, a protein expressed on monocytes, macrophages and neutrophils. Such antibodies find utility in the treatment of individuals with an inflammatory disease, such as rheumatoid arthritis and inflammatory bowel disease.
Public/Granted literature
- US20190194321A1 ANTIBODIES THAT BIND AND BLOCK TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS-1 (TREM-1) Public/Granted day:2019-06-27
Information query
